FDA approves Novartis Kisqali® to reduce risk of recurrence in …
WEB3 days ago · Ad hoc announcement pursuant to Art. 53 LR. Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1,2; Kisqali ® (ribociclib) significantly reduced the risk of recurrence by 25% vs. endocrine therapy (ET) alone; consistent benefit and a well-tolerated safety profile ...
FDA approves Novartis Kisqali® to reduce risk of recurrence in …
WEB3 days ago · Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy 1,2; Kisqali ...
Pelareorep Plus Paclitaxel Extends Survival in HR+/HER2– Breast …
WEB1 day ago · The 2-year survival rate in the pelareorep plus paclitaxel group was 64% vs 33% in the paclitaxel monotherapy group. For progression-free survival (PFS), the final median was 12.1 months for the pelareorep/paclitaxel arm compared with 6.4 months in the paclitaxel monotherapy arm, resulting in a 5.7-month PFS benefit (HR, 0.39).
FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer
WEB3 days ago · FDA approves Novartis Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer. News release. Novartis. September 17, 2024. Accessed September 17, 2024. ...
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2
WEB2 days ago · READ MORE: FDA Approves Kisqali Regimen for HR+/HER2- Early Breast Cancer. In terms of specific subgroup data, the iDFS rates among patients with stage 2 disease were 94.4% versus 92.7% at three years with a change of 1.7% and 93.9% versus 89.6% at four years with Kisqali /NSAI versus NSAI alone with a …
FDA approves Novartis Kisqali® to reduce risk of recurrence
WEB3 days ago · Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy. 1,2. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and ...
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 …
WEB2 days ago · Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced positive clinical results from BRACELET-1, its ...
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic …
WEB21 hours ago · The second-line treatment of HR-positive, HER2-negative metastatic breast cancer has drastically evolved in recent years, putting a focus on ESR1 mutation monitoring at center stage, explained Dana J. Tolman, MSN, APRN, FNP-C. “The very first medication that we started out with [for this patient population] was the SERM, tamoxifen.
Ribociclib Combo Approved in HR+/HER2- Stage II-III Early Breast …
WEB4 days ago · The FDA has approved ribociclib (Kisqali) plus an aromatase inhibitor as adjuvant treatment for patients with hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer at high risk of recurrence, according to a press release from Novartis. 1. The dosing information included a once daily oral dose of ribociclib at 400 ...
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2
WEBFeb 3, 2023 · Trodelvy is also approved in the U.S. to treat certain patients with pre-treated HR+/HER2- metastatic breast cancer and has an accelerated approval for treatment of certain patients with second-line metastatic urothelial cancer; see below for …